UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 21, 2022
RUBIUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 001-38586 | | 46-2688109 |
(State or other jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification Number) |
399 Binney Street, Suite 300
Cambridge, MA | | 02139 |
| (Address of registrant’s principal executive office) | | (Zip code) |
(617) 679-9600
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | RUBY | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.01. | Completion of Acquisition or Disposition of Assets. |
On December 21, 2022, Rubius Therapeutics, Inc. (the “Company”) completed its previously announced sale of certain real property located at 100 Technology Way, Smithfield, Rhode Island 02917 (Map 49, Lot 219) and 30 Hanton City Road, Smithfield, Rhode Island 02917 (Map 49, Lot 78), together with the buildings and improvements thereon, including the Company's manufacturing facility, and certain fixtures and personal property located in or on the real property (collectively, the “Property”), as previously described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2022 (the “Prior Report”). As previously described in the Prior Report, the Company sold the Property to DIV Acquisition V, LLC for an aggregate purchase price of $18,500,000, subject to adjustment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 21, 2022 | RUBIUS THERAPEUTICS, INC. |
| | | |
| | By: | /s/ Dannielle Appelhans |
| | | Dannielle Appelhans |
| | | Chief Executive Officer |
